{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.013","upperLimit":"0.987","value":"0.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2"}],"units":"Participants"}],"description":"Patients enrolled will have non-measurable disease based on imaging at baseline. Patients will be assessed for a response after 6 months of treatment using the results of a biopsy and cytology test. A complete response (CR) is defined as having a negative biopsy and negative urine cytology at 6 months from registration after finishing of concurrent RT and immunotherapy. Imaging of abdomen and pelvis confirming no systemic disease within 4 weeks of cystoscopy will be completed.\n\nThe proportion of patients reporting a CR is reported here with confidence intervals for the true success proportion using the binomial distribution.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received avelumab IV over 60 minutes every 14 days for a total of 10 courses in the absence of disease progression or unacceptable toxicity. Beginning 29 days after the first dose of avelumab, participants received 35 mg/m\\^2/day cisplatin IV starting on day 1 of courses 3-5 for up to 6 weeks in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Avelumab and Cisplatin IV"}],"paramType":"NUMBER","populationDescription":"All patients who registered and began protocol treatment are included in this analysis.","reportingStatus":"POSTED","timeFrame":"At 6 months from registration","title":"Proportion of Participants With Complete Response (At 6 Months)","type":"PRIMARY","unitOfMeasure":"proportion of participants"}